Clinical Trial Update: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating FOLFIRI plus panitumumab in RAS and BRAF wild-type metastatic colorectal cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Carcinoma

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Panitumumab (panitumumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-08-16